Latest market price
107.88
-1.43-1.31%
OverviewShort InterestFilings
INSMQT25Insmed Incorporated·NASDAQ
107.88-1.31%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
INCY-0.07%$119.95UTHR+1.13%$602.88ROIV+0.75%$36.16BNTX+0.56%$88.02ALNY-0.26%$157.59EXEL+2.94%$72.19GMAB+1.34%$55.66ASND+0.98%$251.42
Snapshot
Index—P/E—EPS (ttm)-2.82Insider Own1.06%Shs Outstand218.38MPerf Week17.12%
Market Cap23.87BForward P/E167.63EPS next Y0.65Insider Trans-20.49%Shs Float215.15MPerf Month-1.63%
Enterprise Value23.45BPEG—EPS next Q-0.21Short Float6.26%Perf Quarter10.69%
Income-605.00MP/S15.72EPS this Y—Short Ratio5.17Perf Half Y-21.93%
Sales1.52BP/B32.88EPS next Y—ROA-27.21%Short Interest13.48MPerf YTD-37.19%
Book/sh3.32P/C20.81EPS next 5Y—ROE-82.75%52W High212.75 -49.29%Perf Year-43.72%
Cash/sh5.25P/FCF—EPS past 3/5Y—ROIC-32.75%52W Low90.39 19.35%Perf 3Y327.83%
Dividend Est.—EV/EBITDA—Sales past 3/5Y35.24% 29.88%Gross Margin84.26%Volatility5.29% 3.73%Perf 5Y303.66%
Dividend TTM—EV/Sales15.44EPS Y/Y TTM—Oper. Margin-35.59%ATR (14)4.64Perf 10Y678.56%
Dividend Ex-Date—Quick Ratio2.59Sales Y/Y TTM240.58%Profit Margin-39.85%RSI (14)57.22Recom2.11
Dividend Gr. 3/5Y—Current Ratio2.86EPS Q/Q73.71%SMA209.92%Beta0.82Target Price191.06
Payout0.00%Debt/Eq1.00Sales Q/Q269.01%SMA50-2.69%Rel Volume1.46Prev Close109.31
Employees1,664LT Debt/Eq0.99EarningsFeb 18SMA200-12.67%Avg Volume2.91MPrice107.88
IPO DateJun 01, 2000Option/ShortYes / YesEPS/Sales Surpr.-20.19% 4.81%Net Debt/EBITDA—Volume4,237,072Change-1.31%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-02-26ReiteratedGuggenheimBuy$205 → $201
Oct-29-26ReiteratedStifel NicolausBuy$205 → $195
Oct-29-26ReiteratedMizuho SecuritiesOutperform$195 → $154
Oct-21-26ReiteratedMorgan StanleyOverweight$218 → $213
Oct-20-26ReiteratedRaymond James$187 → $173
Oct-12-26ReiteratedRaymond James$200 → $207
Oct-12-26DowngradeWolfe ResearchOutperform → Peer Perform
Sep-30-26ReiteratedBarclaysOverweight$231 → $207
Sep-24-26ResumedGoldman SachsBuy$225 → $188
Sep-15-26ReiteratedRoth CapitalBuy$212 → $198
Latest News· Times ET
Oct-30-26
Oct-30-2609:48PM
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcriptseekingalpha.com
11:31AM
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidancezacks.com
Oct-29-26
Oct-29-2602:40PM
Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”Yahoo
02:15PM
What Insmed (INSM) Said on Its Q3 Earnings Callmarketbeat.com
10:31AM
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimateszacks.com
09:36AM
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimateszacks.com
07:00AM
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Updateprnewswire.com
Oct-28-26
Oct-28-2604:05AM
Citizens Financial Group Inc. RI Makes New Investment in Insmed, Inc. $INSMdefenseworld.net
Oct-22-26
Oct-22-2602:30PM
$100 Invested In Insmed 15 Years Ago Would Be Worth This Much TodayBenzinga
11:02AM
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Releasezacks.com
Oct-20-26
Oct-20-2607:00AM
Insmed Appoints Two New Directors to Its Boardprnewswire.com
Oct-19-26
Oct-19-2607:00AM
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japanprnewswire.com
Oct-15-26
Oct-15-2607:00AM
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026prnewswire.com
Oct-14-26
Oct-14-2607:00AM
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026prnewswire.com
04:09AM
Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSMdefenseworld.net
Company

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,519606364305—————
Cost of Goods Sold Incl. D&A2391258666—————
Gross Profit1,280482278240—————
Selling, General and Administrative Excl. Other959701461345—————
Research and Development944771598571—————
Other Operating Expense-811869733—————
Operating Income-541-1,177-878-710—————
Interest Expense81848582—————
Unusual Expense
—————————
Non-Operating Income (Expense)23-115344—————
Net Income Before Taxes-598-1,272-910-747—————
Income Taxes8543—————
Consolidated Net Income-605-1,277-914-750—————
Net Income From Continuing Operations-605-1,277-914-750—————
Net Income-605-1,277-914-750—————
EPS (Recurring)-2.82-6.41-5.57-5.34—————
EPS (Basic, Before Extraordinaries)-2.82-6.41-5.57-5.34—————
EPS (Diluted)-2.82-6.41-5.57-5.34—————
EBITDA-494-1,172-819-660—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio15.5561.4631.1114.22—————
Gross Margin84.2779.5476.3778.69—————
Operating Margin-35.62-194.22-241.21-232.79—————
Net Margin-39.83-210.73-251.10-245.90—————
Shares Outstanding219214164140—————
Market Capitalization23,62637,24511,3234,339—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$229.34$190.49$151.64$112.80$73.95● Close Price0.00M9.02M18.05M27.07M36.10MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Brennan David RDirectorSep 09 '26Sale124.0025,0003,100,00039,238Sep 11
SHAROKY MELVIN MDDirectorAug 17 '26Sale127.535,000637,6500Aug 19
Adsett RogerChief Operating OfficerAug 10 '26Sale133.27239,85031,964,81098,744Aug 12
Adsett RogerChief Operating OfficerAug 10 '26Option Exercise20.45239,8504,905,570338,594Aug 12
Flammer Martina M.D.Chief Medical OfficerAug 06 '26Sale128.6127,1733,494,83860,486Aug 07
Flammer Martina M.D.Chief Medical OfficerAug 06 '26Option Exercise21.2027,173576,12687,659Aug 07
Lewis WilliamChair and CEOJul 23 '26Option Exercise24.9410,700266,870269,758Jul 24
Lewis WilliamChair and CEOJul 23 '26Sale106.0610,7001,134,890259,058Jul 24
Lewis WilliamChair and CEOJul 09 '26Option Exercise24.9410,699266,839269,757Jul 10
Lewis WilliamChair and CEOJul 09 '26Sale117.4010,6991,256,085259,058Jul 10
Flammer Martina M.D.Chief Medical OfficerJul 06 '26Sale109.9812,3021,352,93260,486Jul 08
Flammer Martina M.D.Chief Medical OfficerJul 06 '26Option Exercise25.8012,302317,44572,788Jul 08
Lewis WilliamChair and CEOJun 25 '26Option Exercise24.9421,398533,679280,315Jun 26
Lewis WilliamChair and CEOJun 25 '26Sale103.3221,3982,210,763258,917Jun 26
Smith Michael AlexanderChief Legal OfficerJun 22 '26Sale95.821,806173,05137,648Jun 24
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.